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We examined whether Angelicae Dahuricae Radix (AR) suppresses the development of atopic dermatitis (AD)-like skin lesions
induced by Dermatophagoides farinae in NC/Nga mice. To investigate the eﬀect of AR, we measured the AD severity score,
measured plasma levels of IgE and histamine, and performed histological analysis in NC/Nga mice. We also conﬁrmed the anti-
inﬂammatory eﬀects of AR by measuring TARC/CCL17 production from LPS-treated RAW 264.7 cells and mRNA levels of TARC
and MDC/CCL22 in TNF-α/IFN-γ-treated HaCaT cells. 10mg/day of AR extract was applied for 4 weeks to NC/Nga mice. Both
the AR extract and 0.1% tacrolimus suppressed the development of AD-like skin lesions and reduced dermatitis scores of the back
andearskin.ARextractscausedaninhibitionofhistologicalchangesinducedbyrepeatedapplicationofD.farinaeandareduction
of IgE and histamine levels in plasma (P<0.05). Furthermore, NO production in LPS-treated RAW 264.7 cells was diminished in
a dose-dependent manner, and hTARC production and TARC and MDC mRNA levels in TNF-α/IFN-γ-treated HaCaT cells were
diminished by AR. The inhibitory eﬀect of AR on NO, TARC and MDC production may be associated with the suppression of
AD-like skin lesions in D. farinae-induced NC/Nga mice.
1.Introduction
Angelicae Dahuricae Radix (AR) is the dried root of Angelica
dahurica (FISCH.)B ENTH. et HOOKER F (Umbelliferae). AR has
been used for the treatment of colds, headaches, toothaches,
coryza, and psoriasis in Korean traditional medicine [1].
There have been reports that AR has anti-inﬂammatory [2],
antioxidant[3],andcytochromeP450activity[4].Themajor
compounds of AR are imperatorin and coumarin. These
compounds have also been shown to be eﬀective agents for
anticancer responses [5] as well as for the induction of beta-
endorphin [6], antihistamine [7], and antioxidative activity
[8].
Atopic dermatitis (AD) is a chronic, relapsing skin disor-
der involving the interplay between migrating lymphocytes
and epidermal keratinocytes [9]. AD is a clinical syndrome
that is characterized by pruritic and dry skin lesions.
Although topical steroids and immunosuppressive drug
therapies are used to treat AD patients, these therapies result
in adverse eﬀects. At present, many researchers are exploring
drugs traditionally used in herbal medicine, which have few
adverse eﬀects and excellent eﬃcacy for dermatology [10].
Our study shows that AR is beneﬁcial for treating AD-like
skin lesions induced by the dust mite Dermatophagoides
farinae on NC/Nga mice.
Th2 cells are induced to migrate to speciﬁc anatomic
locations by thymus- and activation-regulated chemokines
(TARC/CCL17) and macrophage-derived chemokines
(MDC/CCL22), and regulated on activation which are
speciﬁc ligands for CCR4 [11, 12]. TARC and MDC have
been found to be associated with AD in many reports. The
serum levels of TARC and MDC have been shown to be
markedly elevated and to correlate with disease severity in
patients with AD [13, 14]. In the present study, we examined
the eﬀect of AR on D. farinae-induced AD-like skin lesions
on NC/Nga mice. We also conﬁrmed the anti-inﬂammatory
eﬀect of AR on LPS-induced RAW 264.7 cells and the
antiallergy eﬀect of AR on recombinant human tumor2 Evidence-Based Complementary and Alternative Medicine
necrosis factor-α (TNF-α)/recombinant human interferon-
γ (IFN-γ)-treated HaCaT cells.
2.MaterialsandMethods
2.1. Animals. Eight-week-old male NC/Nga mice were pur-
chased from Central Laboratory Animal Inc. (Seoul, Korea)
and housed in an air-conditioned room maintained at 24 ±
2◦Cand55±15%humidity.Allproceduresinvolvinganimals
were conducted in accordance with the guidelines of the
Institutional Animal Care and Use committee of the Korea
Institute of Oriental Medicine (no. 09-173).
2.2. Chemicals and Reagents. Oxypeucedanin, oxypeuce-
danin hydrate, and byakangelicin were isolated from A.
dahurica by a series of chromatography procedures. The
purity of each compound was determined to be above
95% by HPLC analysis. Nodakenin was obtained from
Wako (Osaka, Japan). Imperatorin and isoimperatorin were
purchased from ChromaDex (Santa Ana, CA, USA). HPLC-
grade reagents, methanol, acetonitrile, and water were
obtained from J.T. Baker (Phillipsburg, NJ, USA). Other
c h e m i c a l sw e r eo fa n a l y t i c a lg r a d e .AD. farinae ointment
waspurchasedfromBiostir Inc.(Hyogo,Japan).Thepositive
control animals were treated with a 0.1% tacrolimus, an
immunosuppressive drug (Protopic, Astellas, NY, USA).
Human recombinant TNF-α,I F N - γ, and TARC enzyme-
linked immunosorbent assay (ELISA) kits were obtained
from R&D Systems (MN, USA). Forskolin, NG-methyl-
L-arginine (NMMA) and silymarin were purchased from
Sigma-Aldrich (MO, USA). Mouse IgE and histamine ELISA
kits are the products of Bethyl Laboratories Inc. (TX, USA)
and Oxford biomedical research (MI, USA), respectively.
2.3. Preparation of AR Extract and Analysis of Chemical
Components. Two-hundred grams of Angelicae Dahuricae
Radix (AR; H-MAX, Korea) was obtained and extracted
using a 10-fold volume (w/v) of extraction solvent (70%
ethanol) to prepare the liquid extract. The extract was
concentrated and then freeze dried to prepare a powdered
extract (62.19g). The extraction yield was 31.10%.
HPLC was used to analyze the chemical components of
the AR extract. The chemicals used to identify compounds
in the AR extract included the following: oxypeucedanin,
oxypeucedanin hydrate, byakangelicin, nodakenin, impera-
torin, and isoimperatorin. The HPLC retention times of the
sixmaincoumarincompoundswereapproximately8.9,14.4,
14.9, 23.3, 28.3, and 31.1min for nodakenin, oxypeucedanin
hydrate, byakangelicin, oxypeucedanin, imperatorin, and
isoimperatorin, respectively [15].
2.4. Sensitization. AD-like skin lesions were induced in 10-
week-old male NC/Nga mice using D. farinae extract as
described by the manufacturer [16]. An ointment of D.
farinae extract (Biostir AD) was purchased from Biostir Inc.
(Hyogo, Japan) and applied twice per week for 4 weeks.
Brieﬂy, the hair on the upper back was shaved, and then
200μL of 10% (w/v) sodium dodecyl sulfate (SDS) was
applied for barrier disruption to the shaved dorsal skin and
bothsurfacesofeachearuntilthesecondtreatment.Afterthe
secondtreatment,200μLof 4% (w/v) SDSwasapplied to the
skin and ears before topical application of 50mg of Biostir
AD. At the start of the experiment, mice were randomized
to one of four groups (n = 5 each): untreated con-
trols (70% ethanol; Control), the Biostir AD-treated group
(50mg/mouse; D. farinae), the Biostir AD with Protopic-
treatedgroup(50mg/mouse;tacrolimus),andtheBiostirAD
with AR extract-treated group (10mg/mouse/70% ethanol;
AR). AR extract was dissolved into 70% ethanol. Ethanol
(70%) was given to the animals in the vehicle control group.
2.5. Dermatitis Score. T h es e v e r i t yo fd e r m a t i t i sw a si n v e s -
tigated macroscopically. The back skin and skin lesions on
both ears were scored according to the following symp-
toms: erythema/hemorrhage, edema, excoriation/erosion,
and scaling/dryness. The severity score was deﬁned as the
sum of individual scores, graded as follows: 0 (no symptom),
1 (mild), 2 (moderate), and 3 (severe).
2.6. Histopathology. After sacriﬁcing the mice, the back skin
and both ears were ﬁxed in 10% (v/v) neutral buﬀered
formalin for 24hr at 4◦C .T i s s u e sw e r en e x te m b e d d e d
in paraﬃn and thin sectioned (4μm thickness). Sections
were then stained with H&E solution (hematoxylin and
eosin, Sigma-Aldrich Inc., MO, USA) and subsequently
mounted under cover slips using Dako-mounting medium
(Dakocytomation, Denmark). Photographs were captured
using a photometric Quanix digital camera, and images
were assembled in Adobe Photoshop. To measure mast cell
inﬁltration, skin sections were stained with toluidine blue,
and the numbers of mast cells in four randomly chosen
regions were counted.
2.7. ELISA. Blood samples were obtained from mice, and
plasma was separated by centrifugation at 10,000rpm for
10min at 4◦C. Plasma was collected and stored at −80◦C.
Total plasma IgE and histamine levels from treated NC/Nga
mice were measured by ELISA according to the manufac-
turer’s instructions.
2.8. Cell Culture. The murine macrophage cell line RAW
264.7 was obtained from the American Type Culture
Collection (ATCC, Rockville, MD, USA). The cells were
maintained in DMEM media containing 5.5% FBS and 1%
P&S (100U/mL of penicillin and 100μg/mL of strepto-
mycin) in a humidiﬁed 5% CO2 atmosphere. The human
keratinocyte cell line HaCaT, provided by professor Nakyung
Lee at Sejeong University, was cultured in DMEM with 10%
(v/v) FBS and 1% P&S. RAW 264.7 cells and HaCaT cells
were seeded at a density of 2.5 × 103 cells/well and 1.0 ×
103 cells/well, respectively, for proliferation analysis for 24hr.
ThecellcountingKit-8reagent(CCK-8,Dojindo,Japan)was
added and incubated for 4hr. We measured the absorbance
at 450nm using a Benchmark Plus ELISA reader (BIO-
RAD, Japan), and the percentages of proliferating cells were
calculated.Evidence-Based Complementary and Alternative Medicine 3
0 1234
Cont
Tacrolimus
(weeks)
AR
D. farinae
(a)
0
2
4
6
8
10
12
01234
(weeks)
S
c
o
r
e
Tacrolimus
AR
D. farinae
∗
(b)
Ear
Skin
AR Cont Tacrolimus D. farinae
(c)
Figure 1: Severity scores and histological changes of treated backs and ears in NC/Nga mice. (a) Representative features and histological
changes following consecutive administration of Angelicae Dahuricae Radix (AR) or tacrolimus to Dermatophagoides farinae-induced AD-
like lesions on the back and ears. The images show the back and ears 4 weeks after sensitization. (b) Eﬀect of consecutive administration
of AR or tacrolimus on dermatitis score of D. farinae-induced AD-like lesions on the back and ears. AR or tacrolimus were administrated
once daily for 4 weeks. (c) Histological features of AD-like lesions treated with AR. The dermatitis scores were evaluated by the procedures
described in Materials and Methods (mean ± SEM (n = 5), ∗: P<0.05, compared with D. farinae-induced group).
2.9. Measurement of Nitric Oxide (NO). RAW 264.7 cells
were seeded at a density of 2.5 × 105 cells in a 48-well plate
for the NO assay. After 18 hour incubation, the cells were
stimulated with 1μg/mL of LPS in the presence or absence of
AR extracts for the indicated periods. A griess reagent system
(Promega. WI. USA) was used to measure the production
and inhibition of NO in culture supernatants. Brieﬂy, a 50-
μL/well sample was incubated at room temperature with
1% sulfanilamide for 10min and 1% α-naphthylamine for
10min. The absorbance was evaluated at 535nm using a
calibration curve with standard.
2.10. Measurement of hTARC. HaCaT cells were seeded at a
density of 1.0 × 106 cells/well in 6-well plates for the hTARC
assay. After 24hr, the cells were washed and incubated with
1mLserum-freemediacontainingTNF-α(10ng/mL)/IFN-γ
(10ng/mL)plusARextractfor24hr.Cellsweresubsequently
incubated with AR extract (200, 500, or 1000μg/mL) for
24hr; other groups of cells were treated with forskolin (10
and 30μM) and silymarin (20 and 50μg/mL) as positive
controls. The absorbance was evaluated using a Benchmark
Plus ELISA reader at 450nm using a calibration curve with a
standard.
2.11. Gene Expression (RT-PCR). After a 24-hr incubation of
cells as described above, total RNA was isolated using TRIzol
reagent (Invitrogen Life Technologies, CA, USA). cDNA was
synthesized from total RNA (2μg) using an iScript Select
cDNA Synthesis kit (Bio-Rad, CA, USA) according to the
manufacturer’s instructions. For PCR ampliﬁcation, we used
the following speciﬁc primers for the mRNAs: TARC (for-
ward: 5 -actgctccagggatgccatcgttttt-3 ,r e v e r s e :5  -acaagg-
ggatgggatctccctcactg-3 ); MDC (forward: 5 -aggacagagcat-
ggctcgcctacaga-3 ,r e v e r s e :5  -taatggcagggaggtagggctcctga-
3 ); hGAPDH (forward: 5 -aagggtcatcatctctgccc-3 , reverse:
5 -gtgatggcatggactgtggt-3 ), which were expected to yield
fragments of 270bp, 362bp, and 204bp, respectively.
2.12. Statistical Analysis. Data are reported as the
means ± SEM and were compared by ANOVA followed
by the Bonferroni multiple comparison method. For score
data analysis, data were compared by Wilcoxon statistics4 Evidence-Based Complementary and Alternative Medicine
after Kruskalis-Wallis test (SYSTAT 10.0., SPSS Inc., USA) A
P-value < 0.05 was deﬁned as statistically signiﬁcant.
3. Results
3.1. Histological Analysis. Skin from treated NC/Nga mice
was investigated once a week for 4 weeks (Figure 1(a)).
The control group showed no physical signs of dermati-
tis, erythema/hemorrhage, edema, excoriation/erosion, or
scaling/dryness. In contrast, the severity scores of the D.
farinae group gradually increased after sensitization. The
groups receiving tacrolimus and AR treatments both showed
areductioninthedevelopment ofAD-like skin lesions,anda
signiﬁcant diﬀerence in lesions was observed between 2 and
4 weeks. The severity scores are shown in Figure 1(b).W e
show that the tacrolimus and AR treatments suppressed AD-
like skin lesions compared with treatments with D. farinae
alone.
3.2. Histopathological Observation. Histopathological ﬁnd-
ingsfromthebackskinandearskinareshowninFigure 1(c).
Topical application of D. farinae increased the thickness of
back and ear skin. In the tacrolimus- and AR-treated groups,
there were fewer prominent inﬂammatory changes, such as
erosion and hyperplasia of epidermal and dermal tissues.
3.3. Plasma Levels of Histamine and IgE. The histamine level
in plasma is shown in Figure 2(a).T h eD. farinae-treated
group (1.27 ± 0.15μM) had an increase in histamine levels
compared with the control group (0.91 ± 0.16μM) (P<
0.01). AR treatment reduced the histamine level signiﬁcantly
(0.82±0.0.08μM; P<0.05). The group receiving tacrolimus
also had decreased histamine levels (1.03±0.10μM), but this
decrease did not reach statistical signiﬁcance.
Similar trends were seen with IgE levels in plasma. The
control group secreted 56.67 ± 14.91ng/mL IgE. However,
the D. farinae-treated group had a 4.7-fold increase in IgE
plasma level (266.54 ± 14.92ng/mL). When AR was applied
to the AD-like lesions, the IgE level was reduced 1.44-fold
(184.46 ± 19.70ng/mL). However, there was no signiﬁcant
diﬀerence in IgE levels in the tacrolimus group compared
with D. farinae-treated group (Figure 2(b)).
3.4. Eﬀects of AR on NO and hTARC Production. The eﬀects
of AR on NO production were examined in LPS-induced
RAW 264.7 cells. Control cells released 2.21 ± 0.18μMo f
nitrite during 18hr of incubation. Upon exposure to LPS
alone, the cells released 51.01±2.28μM nitrite (Figure 3(a)).
For the positive control, NMMA inhibited LPS-induced
nitrite production in a dose-dependent manner, correspond-
ing to a 20% inhibition at 10μM and a 56% inhibition
at 100μM. Additionally, NO production was inhibited by
AR in a dose-dependent manner, corresponding to an 8%
inhibition at 15μg/mL and a 51% inhibition at 150μg/mL.
The eﬀects of AR on hTARC production were exam-
ined in TNF-α/IFN-γ-induced HaCaT cells. As a positive
control for decreasing hTARC levels, we used silymarin (20,
50μg/mL) and forskolin (10, 30μM) to inhibit cAMP. The
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Figure 2: Eﬀect of Angelicae Dahuricae Radix (AR) on plasma
levels of histamine and IgE in Dermatophagoides farinae-induced
AD-like lesions in NC/Nga mice. The groups were untreated
(cont), D. farinae plus vehicle-treated (D. farinae), D. farinae plus
tacrolimus-treated (tacrolimus), and D. farinae plus AR-treated
(AR) NC/Nga mice. The plasma concentrations of histamine (a)
and IgE (b) were measured by ELISA (mean ± SEM, n = 5), #:
P<0.05, ##: P<0.01 compared with control group, ∗: P<0.05, ∗∗:
P<0.01 compared with D. farinae-induced group.
control cells secreted 4.64 ± 0.54pg/mL hTARC. When each
cell type was treated with 10ng/mL of TNF-α/IFN-γ, the
hTARC level increased 5.3-fold (24.72 ± 3.24pg/mL). We
conﬁrmed that the positive controls induced decreased levels
of hTARC in a dose-dependent manner; silymarin-treated
cells secreted 9.14 ± 0.29pg/mL at 20μg/mL and 3.63 ±
0.56pg/mL at 50μg/mL, and forskolin-treated cells secreted
13.50±0.54pg/mLat10μMand5.72±1.23pg/mLat30μM.
AR inhibited TNF-α/IFN-γ–induced hTARC production
in a dose-dependent manner, corresponding to 26.89 ±
1.00pg/mL, 14.95 ± 0.56pg/mL, and 3.41 ± 1.40pg/mL at
60, 150 and 300μg/mL, respectively (Figure 3(b)).
3.5. AR Inhibits the Expression of TARC, MDC, and RANTES.
We measured the ability of AR to inhibit transcription
of TARC and MDC using RT-PCR. Expression of TARC
and MDC was stimulated with TNF-α/IFN-γ treatment of
HaCaT. In the positive controls, silymarin and forskolin
suppressed the expression of TARC and MDC. AR inhibitedEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: Inhibitory eﬀects on NO and TARC by Angelicae Dahuricae Radix (AR). The concentrations of NO and TARC in the supernatant
were determined using NO and TARC ELISA assays. (a) RAW 264.7 cells were treated with LPS (1μg/mL) for 18hr. AR inhibited NO
production in a concentration-dependent manner (mean ± SEM (n = 5), #: P<0.05, ##: P<0.01 compared with control group, ∗: P<0.05,
∗∗: P<0.01 compared with the LPS-treated group). (b) HaCaT cells were treated with TNF-α plus IFN-γ (TI) (10ng/mL each) for 24h.
TARC levels were signiﬁcantly suppressed by AR (mean ± SEM, n = 5), #: P<0.05, ##: P<0.01 compared with control group, ∗: P<0.05,
∗∗: P<0.01 compared with TI treatment. (c) The MDC and TARC mRNA expression levels were determined by RT-PCR analysis, and
AR suppressed the mRNA expression of MDC and TARC. The cells were treated with silymarin (10, 20, or 50μg/mL), forskolin (5, 10, or
30μg/mL), or AR (60, 150, or 300μg/mL).
the expression of TARC and MDC in a dose-dependent
manner (Figure 3(c)).
4. Discussion
In this study, we investigated whether AR suppressed the
induction of AD-like skin lesions in D. farinae-induced
NC/Nga mice. The NC/Nga mouse model is one of the
most valuable mouse models of human AD [17]. This model
is used to evaluate drug candidates to treat AD. AD is an
inﬂammatory disorder that is caused by genetics factors and
environmental factors such as dust mites and mold.
Our study conﬁrms that AD-like lesions such as ery-
thema/hemorrhage, edema, excoriation/erosion, and scal-
ing/dryness are observed in the D. farinae-induced model.
In this model, AR signiﬁcantly inhibited the development of
AD-like skin lesions on both the back and ears of mice. The
histological features of the AR-treated group were similar to
those of the control group. These results demonstrate that
topicalARapplicationhasananti-inﬂammatoryeﬀectonthe
AD-like skin lesions on NC/Nga mice. AR also suppressed
the histamine and IgE levels in plasma to levels comparable
to those of the control group. We conﬁrmed that the AR
10mg/mouse suppressed the AD-like skin lesions, so further
experiments carry out application the dose-dependent of AR
extracts and fractions.
Immunosuppressive drugs are very eﬀective in the treat-
ment of AD. Two such drugs, tacrolimus and cyclosporine
(CsA), bind calcineurin and inhibit nuclear factor of acti-
vated T-cell (NF-AT) nuclear translation [18]. Tacrolimus
(0.1%, w/v) is used to treat patients with serious AD over a
short period of time, and it suppresses pruritus in AD-like
lesions. This treatment also avoids direct application onto
inﬂammation lesions. However, we found that because of
adverse eﬀects, this compound is not suitable for use on
injuries. In our study, tacrolimus inhibited the increased
histamine levels in plasma related with pruritus, whereas
the IgE levels were increased by tacrolimus. Haniﬁn et al.
reported that the most common application site adverse
events of tacrolimus were pruritus, skin burning (e.g., burn-
ingorwarmthsensation,stinging),andskininfection(which
included all cutaneous infections not otherwise speciﬁed,
e.g., bacterial infections, molluscum, and pyoderma) [19].
So we changed the positive control to prednisolone in the6 Evidence-Based Complementary and Alternative Medicine
further study (see Figure 1S in Supplementary Material
available online at doi:10.1155/2012/743075).
To investigate the anti-inﬂammatory eﬀect of AR, we
estimated NO production in LPS-treated RAW 264.7 cells.
It has been shown that physiological levels of NO can play
animportantroleasanimmuneregulator,neurotransmitter,
andavasodilatorinavarietyoftissues.ThehighlevelsofNO
produced by iNOS, however, have been deﬁned as cytotoxic
in inﬂammation and endotoxemia models [20]. Kang et al.
reported that ethyl acetate fraction from AR had the anti-
inﬂammatory eﬀect [21]. We also conﬁrmed that AR can
inhibit NO production in LPS-treated RAW 264.7 cells in a
dose-dependent manner.
The pathogenesis of AD is mediated by CD4+ Tl y m p h o -
cytes that produce Th2 cytokines. TARC and MDC function
as selective chemoattractants that assist in the recruitment
and migration of Th2 cells [22]. TARC and MDC are
thought to play important roles in the development of skin
diseases such as AD. In this study, we examined the eﬀect of
AR extract on hTARC production in TNF-α/IFN-γ-treated
HaCaT cells and on the mRNA expression of TARC and
MDC. We used forskolin and silymarin as positive controls
to suppress inﬂammation. In another study, forskolin, a
cAMP inhibitor, suppressed TARC and MDC levels in TNF-
α/IFN-γ-treated HaCaT cells [23]. Silymarin was also shown
to inhibit the AD-like skin lesions in D. pteronyssinus-
induced NC/Nga mice and to suppress IL-4 and IgE levels in
plasma [24]. In our study, the AR extract suppressed hTARC
production in TNF-α/IFN-γ-treated HaCaT cells in a dose-
dependent manner. AR and immunosuppressive controls
were also able to inhibit TARC and MDC mRNA levels.
We thought that MDC is less marginal eﬀect than TARC
level. AR may therefore regulate the recruitment of Th2-
type cells to AD lesions by suppressing inﬂammatory mRNA
expression. Someknown antiallergicdrugsarerelatedtoNF-
κB, STAT1, and p38 activation in activated macrophages and
keratinocytes [25]. It will be necessary to assess NF-κBa n d
p38 in the cells used in our study to determine whether the
activity of AR is associated with an anti-inﬂammatory or
antiallergy eﬀect. AR may, therefore, be an important new
anti-inﬂammatory drug for the treatment of Th2-induced
inﬂammation.
In conclusion, topical AR was shown to be eﬀective in
treating AD-like skin lesions in NC/Nga mice and inhibited
AD-related gene (TARC and MDC) expression in TNF-
α/IFN-γ-treated HaCaT cells. Topical application of AR may
therefore be a novel approach to the treatment of AD.
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